Clinical and experimental features of MuSK antibody positive MG in Japan

Authors: Ohta, K.1; Shigemoto, K.2; Fujinami, A.3; Maruyama, N.4; Konishi, T.5; Ohta, M.

Source: European Journal of Neurology, Volume 14, Number 9, September 2007 , pp. 1029-1034(6)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

OR

Price: $48.00 plus tax (Refund Policy)

Abstract:

We investigated the presence of antibodies (Abs) against muscle-specific tyrosine kinase (MuSK) in Japanese myasthenia gravis (MG) patients. MuSK Abs were found in 23 (27%) of 85 generalized seronegative MG (SNMG) patients but not in any of the ocular MG patients. MuSK Ab-positive patients were characterized as having female dominance (M:F, 5:18), age range at onset 18 to 72 (median 45) years old, and prominent oculobulbar symptoms (100%) with neck (57%) or respiratory (35%) muscle weakness. Limb muscle weakness was comparatively less severe (52%), thymoma absent. Most patients had good responses to simple plasma exchange and steroid therapy. MuSK IgG from all 18 patients was exclusively the IgG 4 subclass and bound mainly with the MuSK Ig 1-2 domain. Serial studies of 12 individuals showed a close correlation between the variation in MuSK Ab titers and MG clinical severity (P = 0.01 by Kruskal-Wallis). MuSK Ab titers were sharply decreased in patients who had a good response to early steroid therapy or simple plasma exchange, but there was no change, or a rapid increase on exacerbation after thymectomy. Measurement of MuSK Ab titers aids in the diagnosis of MG and the monitoring of clinical courses after treatment.

Keywords: clinical features; domain; IgG subclass; muscle specific tyrosine kinase; MuSK antibody; myasthenia gravis; seronegative myasthenia gravis

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1468-1331.2007.01870.x

Affiliations: 1: Clinical Research Center, Utano National Hospital, Kyoto, Japan 2: Department of Preventive Medicine, Faculty of Medicine, Graduate School of Ehime University, Ehime, Japan 3: Department of Medical Biochemistry, Kobe Pharmaceutical University, Kobe, Japan 4: Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan 5: Department of Neurology, Utano National Hospital, Kyoto, Japan

Publication date: 2007-09-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page